Respiratory Syncytial Virus (RSV) Therapeutics Global Market Report 2023 – By Drug (Palivizumab, Ribavirin, Other Drugs), By Treatment (Immune Prophylaxis, Supportive Care, Antiviral Medications), By Dosage Form (Oral, Injectable, Other Dosage Forms), By Patient Type (Pediatrics, Adults), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2023-2032

Liver disease therapeutics refers to the treatment of numerous types of liver illnesses, diseases brought on by viruses, including hepatitis A, B, and C. These diseases are mainly caused by consuming more alcohol. The main disease types of liver disease therapeutics are hepatitis, non-alcoholic fatty liver disease, alcohol-induced, and liver cancer. Hepatitis refers to an inflammation of the liver that is caused by a variety of infectious viruses and noninfectious agents leading to a range of health problems, some of which can be fatal. The treatment is antiviral, vaccines, chemotherapy, immunosuppressive agents, and corticosteroids. The end-users included hospitals, ambulatory surgery centers, and other end-users. The global liver diseases therapeutics market is segmented - 1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer 2) By Treatment: Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids 3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users The global liver diseases therapeutics market size is expected to grow from $12.10 billion in 2022 to $13.09 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global liver diseases therapeutics is expected to grow to $17.41 billion in 2027 at a CAGR of 7.4%. The rising prevalence of liver diseases is expected to propel the growth of the liver disease therapeutics market going forward. Liver disease refers to any condition that has been affecting the liver. Liver disease therapeutics help in treating liver diseases through various treatments. For instance, in 2020, according to The Centers for Disease Control and Prevention (CDC), the number of deaths from alcoholic liver disease was 29,505 in the United States. Therefore, the rising prevalence of liver diseases drives the growth of the liver disease therapeutics market. Major players in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, GlaxoSmithKline Plc, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, Abbvie Inc., The Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., and AstraZeneca plc. Strategic partnerships are a key trend gaining popularity in the liver disease therapeutics market. Major companies operating in the liver diseases therapeutics market are undergoing collaborations to strengthen their position in the liver diseases therapeutics market. For instance, in January 2022, Aligos Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, collaborated with Merck & Co, a US-based company operating in liver disease therapeutics. This collaboration is to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis. Further, in January 2021, Novartis, a Switzerland-based company operating in liver disease therapeutics collaborated with Alnylam, a US-based biopharmaceutical company. This collaboration aims to develop liver-targeted therapy as a potential alternative to transplantation for patients experiencing liver failure. In September 2022, GENFIT, a France-based biopharmaceutical company, acquired Versantis for an undisclosed amount. This acquisition of Versantis’ expertise with GENFIT’s know-how in conducting complex development programs in liver diseases, strengthens and accelerates research and development and significantly expands GENFIT’s pipeline. Versantis is a Switzerland-based company operating in liver disease therapeutics. North America was the largest region in the liver diseases therapeutics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the liver diseases therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and the USA. The liver diseases therapeutics market includes revenues earned by entities by diagnosis such as imaging, laboratory tests, endoscopy, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The liver diseases therapeutics market research report is one of a series of new reports from The Business Research Company that provides liver diseases therapeutics market statistics, including liver diseases therapeutics industry global market size, regional shares, competitors with a liver diseases therapeutics market share, detailed liver diseases therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the liver diseases therapeutics industry. This liver diseases therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cystic fibrosis (CF) therapeutics refers to medications that thin and facilitate coughing up lung mucus. It is an inherited disorder that causes severe damage to the lungs, digestive system, and other organs in the body. The main drug classes for cystic fibrosis (CF) therapeutics are pancreatic enzyme supplements, mucolytics, bronchodilators and CFTR modulators. Pancreatic enzyme supplements refer to supplements produced by the pancreas and containing pancreatin or pancrelipase, which is a combination of lipase, amylase, and protease. There are two routes of administration such as oral and inhaled. It includes methods of cystic fibrosis treatment with medication and devices. The global cystic fibrosis (CF) therapeutics market is segmented - 1) By Drug Class: Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, CFTR Modulators 2) By Route Of Administration: Oral, Inhaled 3) By Treatment Method: Medication, Devices The global cystic fibrosis (CF) therapeutics market size is expected to grow from $5.82 billion in 2022 to $6.54 billion in 2023 at a compound annual growth rate (CAGR) of 12.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cystic fibrosis (CF) therapeutics market size is expected to reach $10.11 billion in 2027 at a CAGR of 11.4%. An increase in the number of patients suffering from cystic fibrosis is expected to propel the growth of the cystic fibrosis (CF) therapeutics market going forward. Cystic fibrosis (CF) is an inherited condition that severely harms the body's lungs, digestive system, and other organs. Cystic fibrosis therapeutics are used to treat cystic fibrosis disorder by making the mucus in the lungs thinner and easier to cough up. Thus, an increase in the number of patients suffering from cystic fibrosis is expected to boost the cystic fibrosis (CF) therapeutics market. For instance, in July 2022, according to a report shared by The Cystic Fibrosis (CF) Foundation, a US-based non-profit organisation, there has been an upsurge in the number of people with cystic fibrosis, in 2022 cystic fibrosis affects almost 40,000 children and adults in the United States, and over 105,000 people worldwide have been diagnosed. Therefore, an increase in the number of patients suffering from cystic fibrosis is driving the growth of the cystic fibrosis (CF) therapeutics market. Major players in the cystic fibrosis (CF) therapeutics market are Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Mylan N.V, Novartis AG, F. Hoffmann-La Roche AG, AbbVie Inc., Vertex Pharmaceuticals Incorporated, GlaxoSmithKline PLC, Allergan PLC, AbbVie, Pharmaxis Ltd., Johnson & Johnson, Mylan N.V., Chiesi Farmaceutici SpA, PTC Therapeutics, and Genentech Inc. Product innovations are a key trend gaining popularity in the cystic fibrosis (CF) therapeutics market. Major companies operating in the cystic fibrosis (CF) therapeutics sector are focused on developing new products to gain a competitive advantage in the market. For instance, in March 2021, Chiesi USA, a US-based specialty pharmaceutical company, launched Bronchitol (mannitol) powder, the ‘First and Only’ inhalation powder for cystic fibrosis patients. It is the only dry-powder inhaled mucoactive agent that is small, covert, and transportable, does not need to be refrigerated, and does not need to be cleaned frequently. In October 2020, Roche, a Switzerland-based multinational healthcare company, acquired Enterprise Therapeutics’ cystic fibrosis treatment for an undisclosed amount. With this acquisition, Roche will receive ETD002, the sole Enterprise compound that is now undergoing clinical research. The therapy options for cystic fibrosis are the main focus of the portfolio, but there is also potential for usage in other severe respiratory conditions marked by excessive mucus production. Enterprise Therapeutics is a UK-based drug discovery company operating in cystic fibrosis (CF) therapeutics. North America was the largest region in the cystic fibrosis (CF) therapeutics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global cystic fibrosis (CF) therapeutics market during the forecast period. The regions covered in the global cystic fibrosis (CF) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cystic fibrosis (CF) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cystic fibrosis (CF) therapeutics market includes revenues earned by entities by providing services that include administration of mucus thinner, airway clearance, and antibiotics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cystic fibrosis therapeutics market research report is one of a series of new reports from The Business Research Company that provides cystic fibrosis therapeutics market statistics, including cystic fibrosis therapeutics industry global market size, regional shares, competitors with a cystic fibrosis therapeutics market share, detailed cystic fibrosis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the cystic fibrosis therapeutics industry. This cystic fibrosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plasma protein therapeutics refers to therapies derived from plasma and their recombinant analogs. It is used for the treatment of specific medical conditions by replacing missing or deficient proteins found in plasma, allowing recipients to live healthier and more productive lives. The main products of plasma protein therapeutics are immunoglobulin, albumin, coagulation factor, c1-esterase inhibitors, and other products. Immunoglobulin refers to a component of blood plasma that contains immunoglobulins or antibodies. These are administrated through different routes of administration including intravenous, and subcutaneous and are used for various applications such as primary immunodeficiency disorder (PID), idiopathic thrombocytopenic purpura, secondary immunodeficiency, hereditary angioedema and other applications. The global plasma protein therapeutics market is segmented - 1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products 2) By Route Of Administration: Intravenous, Subcutaneous 3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications The global plasma protein therapeutics market size is expected to grow from $26.25 billion in 2022 to $28.11 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global plasma protein therapeutics market size is expected to reach $35.84 billion in 2027 at a CAGR of 6.3%. An increasing prevalence of autoimmune disorders is expected to propel the growth of the plasma protein therapeutics market going forward. An autoimmune disorder is a condition that emerges when the body's immune system attacks and destroys healthy body cells. Therapeutic plasma exchange is used to treat autoimmune diseases, which emerge when the body misidentifies a part of itself as foreign and produces proteins (known as autoantibodies) that attack the part of the body that is misidentified. For instance, in September 2021, according to Scientific American, a US-based science magazine, autoimmune diseases affect about 4% of the global population. Furthermore, in May 2020, according to the National Library of Medicine, a US-based biomedical library, autoimmunity diseases have a 2 to 1 prevalence rate for women. Therefore, the increasing prevalence of autoimmune disorders is driving the growth of the plasma protein therapeutics market going forward. Major players in the plasma protein therapeutics market are Octapharma AG, CSL Behring LLC, Grifols S.A, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion S.p.A., Shire PLC., LFB GROUP, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions B.V., Bio Products Laboratory Ltd., and MP Biomedicals LLC. Product innovations are a key trend gaining popularity in the plasma protein therapeutic gaining market. Major companies operating in the plasma protein therapeutic sector are focused on innovative products to gain a competitive advantage in the market. For instance, November 2021, Biognosys a Switzerland-based biotechnology company launched an innovative next-Generation blood biomarker discovery solution. The service is intended to assist researchers in deciphering the complexities of the blood proteome and unlocking unbiased discoveries for pharmaceutical and diagnostic development, as well as precision medicine. A unique feature of both solutions is Biognosys' Hyper Reaction Monitoring (HRMTM) technology and its optimized Liquid Chromatography-Mass Spectrometry (LC-MS) workflow. In April 2022, Grifols S.A, a Spain-based pharmaceutical, and chemical manufacturer acquired Tiancheng (Germany) Pharmaceutical Holdings AG for € 1.6 billion ($1.72 billion). This acquisition is expected to accelerate and expand Grifols' product portfolio, increase patient access to plasma therapies, and drive revenue growth and margin expansion. Biotest is a Germany-based healthcare company specializing in innovative hematology and clinical immunology and focused on developing, manufacturing, and marketing plasma proteins and biotherapeutic drugs. North America was the largest region in the plasma protein therapeutics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this global plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the plasma protein therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The plasma protein therapeutics market includes revenues earned by entities by providing therapy for liver disease and bleeding from trauma by using Alpha-1 Proteinase Inhibitors, Hyperimmune Globulins. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The plasma protein therapeutics market research report is one of a series of new reports from The Business Research Company that provides plasma protein therapeutics market statistics, including plasma protein therapeutics industry global market size, regional shares, competitors with a plasma protein therapeutics market share, detailed plasma protein therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the plasma protein therapeutics industry. This plasma protein therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Respiratory devices and equipment (therapeutic and diagnostic) are used to provide medication or assist a patient who is having difficulty in breathing and cannot achieve adequate oxygen levels to maintain life. Patients with respiratory disorders such as asthma, cystic fibrosis, chronic obstructive pulmonary disease, and acute respiratory distress syndrome require respiratory devices. The main types of respiratory devices and equipment are diagnostic devices, therapeutic devices, and monitoring devices. The diagnostic devices are used to diagnose respiratory-related issues. The various therapeutic devices are humidifiers, nebulizers, oxygen concentrators, positive airway pressure (PAP) devices, ventilators, and others. The diagnostic devices involved are spirometer, polysomnographs, and peak flow meters and monitoring devices are pulse oximeters, capnography, and gas analyzers. These provide applications in chronic obstructive pulmonary disease (COPD), asthma, obstructive sleep apnea (OSA), respiratory distress syndrome (RDS), cystic fibrosis, and pneumonia. These are used by hospitals, clinics, home care settings, and ambulatory service centres. The global respiratory devices and equipment (therapeutic and diagnostic) market is segmented - 1) By Type: Diagnostic devices, Therapeutic devices, Monitoring devices 2)By End User: Hospitals, Clinics, Homecare settings, Ambulatory service centers, 3) By Therapeutic Devices: Humidifiers, Nebulizers, Oxygen concentrators, Positive Airway Pressure (PAP) Devices, Ventilators, Other Therapeutic Devices 4) By Diagnostic Devices: Spirometer, Polysomnographs, Peak Flow Meters 5) By Monitoring Devices: Pulse oximeters, Capnographs, Gas analyzers 6) By Application: Chronic Obstructive Pulmonary Disease (COPD), Asthma, Obstructive Sleep Apnea (OSA), Respiratory Distres Syndrome (RDS), Cystic Fibrosis, Pneumonia The global respiratory devices and equipment (therapeutic and diagnostic) market size will grow from $29.09 billion in 2022 to $32.76 billion in 2023 at a compound annual growth rate (CAGR) of 12.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global respiratory devices and equipment (therapeutic and diagnostic) is expected to grow to $50.54 billion in 2027 at a CAGR of 11.5%. The global respiratory devices and equipment (therapeutic and diagnostic) market will be driven by the increase in diseases such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and lung cancer. Growth in the geriatric population, tobacco consumption, allergens, and air pollutants increase the prevalence of respiratory diseases, in turn driving the global therapeutic respiratory devices market. According to World Health Organisation,4.9 million people die due to tobacco consumption, and smoking causes chronic obstructive pulmonary diseases (1 million deaths annually), cardiovascular and respiratory diseases (1.7 million deaths annually), and lung cancer (0.85 million deaths annually). According to an Italian journal, COPD in the U.S. is estimated to be 10% in the population aged 75 years or over. According to Asthma UK, 5.4 million people in the UK are currently receiving treatment for asthma out of these 1.1 million are children and 4.3 million are adults. Major players in the respiratory devices and equipment (therapeutic and diagnostic) market are Smiths Medical, Philips Healthcare, GE Healthcare, Chart Industries, Invacare Corporation, Fisher & Paykel Healthcare Limited, ResMed, Dragerwerk AG, Medtronic PLC., Masimo corp., and CareFusion Corporation. A longer duration of time taken in the approval process of the respiratory devices is restricting the respiratory devices and equipment market growth. Before a new respiratory device is introduced to the market, it takes 7.2 months for the FDA approval process, which adds to development costs to be borne by device manufacturers, thus acting as a restraint hindering the market growth. For instance, FDA reviews about 4,000 submissions every year and takes about 3 to 6 months in clearing most of them. In addition to this, to reduce incidences associated with the respiratory devices and ensure that the devices are safe and have the least adverse reactions, the Medicines and Healthcare products Regulatory Agency (MRHA), UK regulates and monitors the devices by restricting devices for use and sending field safety notice to correct the devices. These stringent approval processes and regulatory policies may impact the respiratory devices and equipment (therapeutic and diagnostic) market market. Companies in the respiratory devices and equipment (therapeutic and diagnostic) market are increasingly investing in enhanced mechanical ventilators for efficient patient management. These mechanical ventilators use artificial intelligence to improve patient management by examining, analyzing, integrating, and incorporating data from extensive sources. These AI-enabled devices ensure consistency even in the absence of expert personnel, improve patients' treatment, limit clinical mistakes, and predict prolonged mechanical ventilation by using artificial intelligence techniques. Some of the major companies offering intelligent mechanical ventilators such as Hamilton Medical AG, Koninklijke Philips N.V., and others. In June 2021, Philips respironics issued a voluntary recall notification after discovering potential health risks related to CPAP, BiPAP and Mechanical ventilator devices. The notification also included a field safety notice for users who did not intend to send the devices for repair. Asia-Pacific was the largest region in respiratory devices and equipment (therapeutic and diagnostic) market in 2022. Western Europe was the second-largest region in the respiratory devices and equipment (therapeutic and diagnostic) market report. The regions covered in the respiratory devices and equipment (therapeutic and diagnostic) analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory devices and equipment (therapeutic and diagnostic) market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, USA, and Australia. The respiratory devices and equipment (therapeutic and diagnostic) market consists of sales of instruments such as humidifiers, nebulizers, oxygen concentrators, positive airway pressure (PAP) devices, ventilators, spirometer, polysomnographs, peak flow meters, pulse oximeters, capnographs, and gas analyzers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The respiratory devices and equipment (therapeutic and diagnostic) market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The respiratory devices and equipment (therapeutic and diagnostic) market research report is one of a series of new reports from The Business Research Company that provides respiratory devices and equipment (therapeutic and diagnostic) market statistics, including respiratory devices and equipment (therapeutic and diagnostic) industry global market size, regional shares, competitors with a respiratory devices and equipment (therapeutic and diagnostic) market share, detailed respiratory devices and equipment (therapeutic and diagnostic) market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory devices and equipment (therapeutic and diagnostic) industry. The respiratory devices and equipment (therapeutic and diagnostic) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Respiratory disposables are used to interface respiratory devices with patients, such as ventilators, nebulizers, and oxygen therapy devices. The main types of respiratory disposables market are masks, tubes, inhalers, and others. A mask is a piece of cloth or other material that is personal protective equipment intended for medical purposes. These are used for disease indications such as asthma, a chronic obstructive pulmonary disorder, tuberculosis, lung cancer, and other chronic respiratory diseases. The applications involved in adult, pediatric, and neonatal. The various end-users are hospitals, clinics, ambulatory care centres, and others. The global respiratory disposables market is segmented - 1) By Type: Masks, Tubes, Inhalers, Other Types 2) By End User: Hospitals, Clinics, Ambulatory Care Centers, Other End Users 3) By Disease Indications: Asthma, Chronic Obstructive Pulmonary Disorder, Tuberculosis, Lung Cancer, Other Chronic Respiratory Diseases 4) By Application: Adult, Pediatric & Neonatal The global respiratory disposables market size will grow from $2.77 billion in 2022 to $3.07 billion in 2023 at a compound annual growth rate (CAGR) of 10.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global respiratory disposables is expected to grow to $4.41 billion in 2027 at a CAGR of 9.5%. The high prevalence rate of respiratory disposables market globally is driving the respiratory disposables market. Excessive smoking, exposure to toxic materials, adverse climate conditions, and air pollution are some of the main causes which are leading to a rise in respiratory diseases such as asthma, lung cancer, Chronic Obstructive Pulmonary Disease (COPD), and obstructive sleep apnea (OSA). According to a study, around 65 million people suffer from chronic obstructive pulmonary disease (COPD) and around 3 million people die every year because of this disease. It was also reported that around 334 million people suffer from asthma diseases caused by air pollution as well as tobacco smoke, toxic disposable devices. These factors are increasing the demand for the treatment of respiratory ailments, thus driving the respiratory disposables market. Major players in the respiratory disposables market are Fisher & Paykel, Becton Dickinson Company, Ambu A/S, Smiths Medical, Armstrong Medical, Teleflex, Philips Respironics, Besmed, ResMed, and Dynarex. The respiratory disposables market is being restrained due to stringent regulatory policies. Regulatory agencies and governments across various countries are imposing stringent restrictions on product approval and launch, this is limiting the market growth. For instance, FDA banned Amphastar Pharmaceutical’s Primatene product, an albuterol CFC inhaler for asthma because ozone-depleting chlorofluorocarbon (CFC) propellants have depleted the ozone layer. The FDA rejected Amphastar’s first attempt to bring a reformulated version of Primatene mist to market. The FDA rejected another application for Primatene Mist. Which resulted in a rise in development costs and potential sales loss due to delays in product launch, thus restraining the Respiratory disposables market. Rapid advances in technology are driving innovation in respiratory disposable manufacturing. Areas of particular development are likely to be AIR gel technology, wearable technologies, and 3D printing technology. These technologies are being used in the manufacturing of respiratory disposables, resulting in higher productivity, lower costs, and higher margins. Companies in this market are increasingly focusing on AIR gel technology, in which gel is incorporated into the bag on the edges of the mask which helps to the protection of the skin and creates a bridge to minimize the irritation of the skin and for effective sealing. For example, Vyair medical prepared Veraseal 2 disposable mask, used for acute care with AIR gel technology and advantage of vented and non-vented versions. Similarly, Sleepnet prepared Mojo ventilation masks with Airgel technology. In the USA, occupational safety and health administration (OSHA) regulates all respiratory medical equipment, guidelines for which are specified in 29 CFR 1910. 134. Under OSHA, the national institute for occupational safety and health/national personal protective technology laboratory (NIOSH/ NPPTL) provides a market approval certificate and FDA approves the product for marketing. Before market approval, all the medical devices should be analyzed appropriately by performing a compatibility test within a hospital environment. They are tested on an Electrical bench and Non-clinical performance testing is also required. Moreover, proper software verification, validation, and hazard analysis must be performed. Labels on the devices are required to include the purpose of the device. In 2021, Medline a Netherland-based medical device company acquired the Hudson RCI brand of respiratory consumables from Teleflex. The acquisition helps Medline's offerings, enlarging the respiratory environment with the highly regarded Hudson RCI products and opening extra opportunities for development and help to customers. Teleflex is a US-based company global provider of medical technologies designed to develop the health and quality of people's lives. Asia-Pacific was the largest region in the global respiratory disposables and equipment market in 2022. Western Europe was the second-largest region in the respiratory disposables market report. The regions covered in the respiratory disposables analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory disposables market include Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The respiratory disposables market consists of sales of instruments such as disposable resuscitators, disposable masks, nasal cannulas, tracheostomy tubes, and other consumables and accessories. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The respiratory disposables market research report is one of a series of new reports from The Business Research Company that provides respiratory disposables market statistics, including respiratory disposables industry global market size, regional shares, competitors with a respiratory disposables market share, detailed respiratory disposables market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory disposables industry. The respiratory disposables market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Respiratory devices and equipment (therapeutic) are used to treat patients with acute or chronic respiratory disorders such as chronic obstructive pulmonary disease (COPD), chronic bronchitis, asthma, sleep disorders, etc. The main products of the respiratory devices and equipment (therapeutic) market are nebulizers, humidifiers, oxygen concentrators, positive airway pressure devices, ventilators, capnographs, and gas analyzers. A nebulizer is a small machine that turns liquid medicine into a mist, sits with the machine, and breathes in by a connected mouthpiece. The various technologies involved in the respiratory devices and equipment are HEPA filter, electrostatic filtration, microsphere separation, hollow fiber filtration, and others. The market covered in this report is segmented by end-users into home care settings and hospitals. The global respiratory devices and equipment (therapeutic) market is segmented - 1) By Product: Nebulizers, Humidifiers, Oxygen Concentrators, Positive Airway Pressure Devices, Ventilators, Capnographs, Gas Analyzers 2) By End-User: Homecare settings, Hospitals 3) By Technology: HEPA Filter, Electrostatic Filtration, Microsphere Separation, Hollow Fiber Filtration, Other Technologies The global respiratory devices and equipment (therapeutic) market size will grow from $18.03 billion in 2022 to $19.90 billion in 2023 at a compound annual growth rate (CAGR) of 10.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global respiratory devices and equipment (therapeutic) is expected to grow to $29.55 billion in 2027 at a CAGR of 10.4%. The respiratory devices and equipment (therapeutic) market is expected to expand rapidly. The fact that COVID-19 is essentially a respiratory ailment has boosted the use of respiratory monitoring devices, in turn contributing to the growth of this market. Currently, there is a huge demand for respiratory devices including ventilators, especially in developing countries. Companies across the globe are focusing on increasing the availability of ventilators, nebulizers, and other respiratory support devices for patients. The rising prevalence of respiratory diseases such as Chronic Obstructive Pulmonary Disorder (COPD) and sleep apnea contributed to the growth of the therapeutic respiratory devices and equipment market. According to World Health Organization, one million people die due to chronic obstructive pulmonary diseases caused by smoking among the 4.9 million people who die due to tobacco consumption and 65 million people suffer from moderate to severe COPD. As per its estimates, COPD is predicted to be the third leading cause of death worldwide and potentially fatal respiratory diseases. Tuberculosis, COPD, and lung cancer will account for about one in five deaths worldwide by 2030. According to National Health Interview Survey by the Centers for Disease Control and Prevention (CDC), the number of adults with diagnosed chronic bronchitis in the USA was 9.0 million. In the USA, it is estimated that 22 million Americans suffer from sleep apnea, with 80% of the cases of moderate and severe obstructive sleep apnea undiagnosed. According to a research study published on American Journal of Respiratory and Critical Care Medicine, in 2021, global prevalence of obstructive sleep apnea was found to be around 20% globally. The increased prevalence of COPD and sleep apnea in the geriatric population is driving the growth of the respiratory devices and equipment (therapeutic) market. Major players in the respiratory devices and equipment (therapeutic) market are Hamilton Medical AG, Koninklijke Philips N.V, Smiths Medica, Ge Healthcare, Philips Health Care, Chart Industries, Invacare Corporation, Fisher & Paykel Healthcare Limited, Resmed, and Dragerwerk AG. Lack of awareness regarding the usage of respiratory devices has always been a major challenge in the therapeutic respiratory device market. Outcomes for patients with chronic respiratory diseases remain poor despite the development of novel therapies. An International Survey conducted on Noninvasive Ventilation Use for Acute Respiratory Failure in General Non-Monitored Wards in 51 countries from 5 continents revealed that 44% of the GPs and physicians reported that they had never performed spirometry to make a diagnosis of COPD and the NIV application in general wards was reported by only 66% of respondents. Limited training and human resources were the most common reasons for not using NIV in general wards. The lack of awareness on the use of respiration devices is negatively affecting the respiratory devices and equipment (therapeutic) market. The companies in the respiratory devices and equipment (therapeutic) market are increasingly using AI to develop respiratory devices to treat Asthma and COPD. Artificial intelligence supports the development of innovative sensors-equipped inhalers which help patients to track their dosage intake. These sensors are durable and consume less power and help caution the patients by noting the differences or fluctuations in respiration. These are used for both add-on and embedded inhalers. These inhalers with sensors can track data automatically and can alert both the doctors and patients about the health condition of the patients. Also, the companies in developing devices such as AI aided imaging systems and AI aided platforms that will act as voice biomarkers. For instance, in March 2022, Respira Labs, a US-based respiratory technology company, launched AI-powered wearable lung monitor ‘Sylvee’. The new product uses acoustic resonance to assess the lung function and detect any variations in the lung function. In March 2020, Masimo, a global leader in noninvasive monitoring technologies acquired NantHealth, Inc's connected care business for an undisclosed amount. NantHealth is a provider a tablet-optimized application that sits on top of our DCX platform to provide clinicians more convenient and ubiquitous access to capture a wide array of patient vitals such as respiratory rate, blood pressure, and heart rate in addition to performing patient assessments. This move of Masimo will leverage its capabilities with NantHealth’s solutions that can enable a more efficient patient rounding and assessment workflow by providing a near real-time stream of data from the patient's bedside unlike periodic sampling typically entered into an EHR hours later. Asia-Pacific was the largest region in the respiratory devices and equipment (therapeutic) market in 2022. Western Europe was the second-largest region in the global respiratory devices and equipment (therapeutic) market share. The regions covered in the global respiratory devices and equipment (therapeutic) market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory devices and equipment (therapeutic) market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The respiratory devices and equipment (therapeutic) market consist of sales of instruments such as nebulizers, oxygen concentrators, positive airway pressure devices, ventilators, inhalers, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The respiratory devices and equipment (therapeutic) market research report is one of a series of new reports from The Business Research Company that provides respiratory devices and equipment (therapeutic) market statistics, including respiratory devices and equipment (therapeutic) industry global market size, regional shares, competitors with a respiratory devices and equipment (therapeutic) market share, detailed respiratory devices and equipment (therapeutic) market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory devices and equipment (therapeutic) industry. This respiratory devices and equipment (therapeutic) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Respiratory devices and equipment (diagnostic) are used in the diagnosis of respiratory disorders such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease. The main products of the respiratory devices and equipment (diagnostic) market are instruments and devices, assays, and reagents. The respiratory instruments and devices are used to diagnose respiratory disorders. The test type included is traditional diagnostic tests, mechanical tests, imaging tests, and molecular diagnostic tests that are used to diagnose chronic obstructive pulmonary disease, lung cancer, asthma, tuberculosis, and other diseases. These are used in hospital/clinical laboratories, physician offices, reference laboratories, and other end users. The global respiratory devices and equipment (diagnostic) market is segmented - 1)By Product: Instruments And Devices, Assays And Reagents 2) By Test Type: Traditional Diagnostic Tests, Mechanical Tests, Imaging Tests, Molecular Diagnostic Tests 3)By Disease Type: Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis, Other Diseases 4) By End User: Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories, Other End Users The global respiratory devices and equipment (diagnostic) market size grew from $6.93 billion in 2022 to $7.51 billion in 2023 at a compound annual growth rate (CAGR) of 8.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global respiratory devices and equipment (diagnostic) is expected to grow from $10.22 billion in 2027 at a CAGR of 8.0%. The increasing prevalence of various respiratory diseases contributed to the global respiratory devices and equipment market growth by increasing the use of diagnostic devices and equipment for diagnosis and treatment. Diseases such as chronic obstructive pulmonary disease (COPD) are more prevalent in the geriatric population. COPD is a type of obstructive lung disease that results in long-term breathing problems. For instance, in June 2021, according to the world health organization data, chronic obstructive pulmonary disease (COPD) is the third disease on the list of causing death in the world. There are about 3.23 million deaths that are caused by chronic obstructive pulmonary disease (COPD).. Thus, the increased number of such cases has surged the demand for diagnostic devices and equipment, therefore driving the growth of respiratory devices and equipment (diagnostic) market. Major players in the respiratory devices and equipment (diagnostic) market are ResMed. Inc., Medtronic PLC., Massimo Corporation, Fisher & Paykel Healthcare Limited, Koninklijke Philips N.V, Smiths Medical, GE Healthcare, Chart Industries, Philips Healthcare, and Becton Dickinson and Company. Stringent regulatory practices are expected to negatively impact the growth of diagnostic respiratory devices in the forecast period. In the USA, respiratory devices undergo a strict approval process as they come under Class III devices (that pose a significant risk to patients) as per the Food and Drug Administration (FDA) classification of medical devices. These devices require clinical evidence that supports their intended use unlike, Class I and II devices, to receive marketing approval. In countries such as China, the approval process for medical devices, especially for devices used for support or sustenance, is strict and time-consuming. Such a process has slowed the entry of medical devices into the market, thus restraining the growth. Companies in the market are increasingly investing in portable and wireless diagnostic respiratory devices. The trend is being driven by the ease of handling, cost-effectiveness, advanced features of these devices, and their suitability for use at home care organizations. Innovative technology-enabled portable respiratory devices are being launched into the market, which, unlike traditional devices, can be used for immediate diagnosis of vital signs, for example, the patients’ respiratory rate and the pulse rate. For instance, in July 2021, Tidal Medical Technologies received U.S FDA approval for the use of its InSee incentive spirometer accessory for detection of medical condition and symptoms of COVID-19 in hospital settings. In June 2020, AireHealth acquired BreathResearch for an undisclosed amount. The deal comprises the acquisition of IP, research, and patents, which include work on machine learning analytics for respiratory condition tracking. BreathResearch is a US-based company engaged in converting the airwaves of breathing into sound waves producing new respiratory analytics which improve health, fitness, and performance. Asia-Pacific was the largest region in the respiratory devices and equipment (diagnostic) market in 2022. North America was the second largest region in the global respiratory devices and equipment (diagnostic) market share. Eastern Europe was the smallest region in the global respiratory devices and equipment (diagnostic) market. The regions covered in the global respiratory devices and equipment (diagnostic) market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory devices and equipment (diagnostic) market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The respiratory devices and equipment (diagnostic) market consist of sales of spirometer, polysomnographs, and peak flow meters and monitoring devices are pulse oximeters, capnography, and gas analyzers that are used for diagnosis of respiratory diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The respiratory devices and equipment (diagnostic) market research report is one of a series of new reports from The Business Research Company that provides respiratory devices and equipment (diagnostic) market statistics, including respiratory devices and equipment (diagnostic) industry global market size, regional shares, competitors with a respiratory devices and equipment (diagnostic) market share, detailed respiratory devices and equipment (diagnostic) market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory devices and equipment (diagnostic) industry. This respiratory devices and equipment (diagnostic) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Respiratory monitoring devices are used to assess the patient's respiratory organs and include patches that are placed on the body to measure respiration and heart rates. The main types of respiratory monitoring devices are capnographs, gas analyzers, pulse oximeters, peak flow meters, spirometers, polysomnography, and others. Capnographs are monitoring devices that measure the concentration of carbon dioxide in exhaled air and display a numerical readout and waveform tracing. The various applications involved are chronic obstructive pulmonary disease (COPD), infectious diseases, asthma, and others that are used by end-users such as laboratories, hospitals, and home use. The global respiratory monitoring devices market is segmented - 1) By Type: Capnographs, Gas Analyzers, Pulse Oximeters, Peak Flow Meters, Spirometers, Polysomnographs, Others Types 2) By End-User: Laboratories, Hospitals, Home Use 3) By Application: Chronic Obstructive Pulmonary Disease (COPD), Infectious Diseases, Asthma, Other Applications The global respiratory monitoring devices market size will grow from $1.32 billion in 2022 to $1.46 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global respiratory monitoring devices is expected to grow to $2.04 billion in 2027 at a CAGR of 8.7%. The market for respiratory monitoring devices is experiencing exponential growth due to the COVID-19 pandemic. The fact that COVID-19 is essentially a respiratory ailment has boosted the use of respiratory monitoring devices to monitor the physiological functions of the lungs during COVID-19 treatment. The rising rate of chronic respiratory diseases is expected to drive the growth of respiratory monitoring devices market in the near future. Chronic respiratory diseases such as asthma, bronchitis, pneumonia, and others resulting from different bacterial and viral infections will boost the demand for respiratory monitoring devices. For example, in according to the National health survey 2021, 4.6% of adults agreed of ever been diagnosed with COPD, emphysema, and chronic bronchitis. Furthermore, according to the national vital statistics system, in 2020, COPD caused 152,657 deaths in the US and bronchitis caused 457 deaths in 2020. The respiratory monitoring devices such as spirometers and pulse oximeters act as essential devices to monitor vital respiratory parameters. Major players in the respiratory monitoring devices market are COVIDien, GE Healthcare, Philips Healthcare, ResMed, Siemens Healthcare, Merck & Co., Calando Pharmaceuticals, Quark Pharmaceuticals, Sirnaomics Inc., and Traversa Therapeutics. The longer duration of time taken in the approval process of respiratory devices is restricting the growth of the respiratory monitoring devices market. Before a new respiratory device is introduced to the market, it takes 7.2 months for the FDA approval process, which adds to the development costs to be borne by device manufacturers, thus acting as a restraint to the market growth. To reduce incidences associated with respiratory devices and ensure that the devices are safe and have the least adverse reactions, regulatory authorities such as the Medicines and Healthcare products Regulatory Agency (MRHA) in the UK regulates and monitors the devices by restricting devices for use and sending field safety notices to correct the devices. These stringent approval processes and regulatory policies may impact the respiratory monitoring devices market. The companies in the market are increasingly launching smart respiratory monitoring devices to diagnose and monitor some respiratory diseases. These smart respiratory monitoring devices are Bluetooth-enabled and can be connected to smartphones to continuously monitor vital respiratory parameters. For instance, in February 2022, Aptar Pharma, a US-based manufacturer of drug delivery systems, launched HeroTracker® Sense. The new offering is a novel digital respiratory health solution that converts a standard meter dose inhaler into a smart connected healthcare device. It is useful for patients to track their MDI usage and help them stick to their prescribed doses. In June 2022, Senzime AB, a US-based manufacturer of patient monitoring systems, acquired Respiratory Motion for an initial cash payment of $19 million. The acquisition will help Senzime to expand its product portfolio in monitoring devices market and extend company’s capabilities. Respiratory motion is a US-based respiratory medical device manufacturer. Asia-Pacific was the largest region in the respiratory monitoring devices market in 2022. North America was the second-largest region in the global respiratory monitoring devices market share. The regions covered in the global respiratory monitoring devices market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory monitoring devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The respiratory monitoring devices market consists of sales of pulse oximeters, capnography, spirometers, polysomnography (PSG), peak flow meters, gas analyzers, and others that are used to monitor respiration and heart rate. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The respiratory monitoring devices market research report is one of a series of new reports from The Business Research Company that provides respiratory monitoring devices market statistics, including respiratory monitoring devices industry global market size, regional shares, competitors with a respiratory monitoring devices market share, detailed respiratory monitoring devices market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory monitoring devices industry. This respiratory monitoring devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.